Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
暂无分享,去创建一个
P. Gobbi | M. Federico | L. Baldini | D. Vallisa | P. Avanzini | V. Silingardi | N. Di Renzo | M. Brugiatelli | M. Carotenuto | M. Lombardo | V. Clò | D. Dini
[1] A. Pileri,et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[2] P. Gobbi,et al. A pilot study on the use of the proMACE‐cytaBOM regimen as a first‐line treatment of advanced follicular non‐Hodgkin's lymphoma , 1997 .
[3] T. Barbui,et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Hagenbeek,et al. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Gallamini,et al. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). , 1997, Haematologica.
[6] A. López-Guillermo,et al. CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial , 1996, European journal of haematology.
[7] L. Gordon,et al. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Bergmann,et al. Vincristine, doxorabicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma — a multicenter phase II study , 1995 .
[9] D. Neuberg,et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Iannitto,et al. Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres. , 1995, European journal of cancer.
[11] E. Iannitto,et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. , 1995, Leukemia & lymphoma.
[12] A. Ho,et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas , 1995 .
[13] P. Gobbi,et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). , 1995, Leukemia & lymphoma.
[14] L. Bergmann,et al. Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Murata,et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non‐Hodgkin's lymphoma , 1994, Cancer.
[16] J. Matthews,et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Alberto De Paoli,et al. A CooDerative Studv on ProMACE-dytaBOM in Aggressive Non-Hodgkin' s Lymphomas , 1994 .
[18] F. Lombardi,et al. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas. , 1994, Leukemia & lymphoma.
[19] C. de Wolf‐Peeters,et al. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] M. Gospodarowicz,et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[21] P. Gobbi,et al. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial. , 1993, Haematologica.
[22] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[23] J. Armitage,et al. Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[24] L. Gordon,et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[25] P. Gobbi,et al. A multicenter randomized trial of two different proMACE-cytaBOM derived protocols in aggressive non-hodgkin's lymphomas (NHL). A preliminary report , 1992 .
[26] A. Zaniboni,et al. A phase II trial of promace‐cytabom in previously untreated non‐hodgkin's lymphoma of intermediate‐ or high‐grade histology , 2006, Hematological oncology.
[27] J. Armitage,et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] W. Hryniuk,et al. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] E. Jaffe,et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] T. Chisesi,et al. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG). , 1991, Leukemia.
[31] R. Fisher,et al. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Gams,et al. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. , 1990, Cancer research.
[33] D Faraggi,et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables , 1990, Cancer.
[34] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Tucker,et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] B. Coiffier,et al. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. , 1989, Blood.
[37] R. Demicheli,et al. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Papish,et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S M Hubbard,et al. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.
[40] F. Mandelli,et al. Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). , 1985, Seminars in oncology.
[41] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[42] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Canellos. Treatment of the non-Hodgkin's lymphomas. , 1978, Medical times.